mesenchymal stem cells for lung disease / Cynata Therap - LARVOL DELTA

Induced pluripotent stem cell-derived mesenchymal stem cells reverse bleomycin-induced pulmonary fibrosis and related lung stiffness. (PubMed, Biomed Pharmacother) - "All these measures were ameliorated by a single or once-weekly intravenous-administration of iPSC-MSCs, with the latter reducing dendritic cell infiltration and lung epithelial damage, whilst promoting anti-inflammatory interleukin (IL)-10 levels to a greater extent. Proteomic profiling of the conditioned media of cultured iPSC-MSCs that were stimulated with TNF-α and IFN-γ, revealed that these stem cells secreted protein levels of immunosuppressive factors that contributed to the anti-fibrotic and therapeutic potential of iPSCs-MSCs as a novel treatment option for IPF."

Journal • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Inflammation • Pneumonia • Pulmonary Disease • Respiratory Diseases • IFNG • TNFA

Cynata (ASX:CYP) unveils promising results in pre-clinical study of lung disease (Kalkine Media) - "Cynata Therapeutics...has concluded a pre-clinical study that provides further evidence in support of the highly potent anti-inflammatory effects of Cynata’s proprietary CymerusTM MSCs. The pre-clinical study outlines the mechanisms of action by which Cymerus MSCs provide therapeutic efficacy as a potential treatment option for IPF (idiopathic pulmonary fibrosis)."

Preclinical • Idiopathic Pulmonary Fibrosis

MEND: The MEseNchymal coviD-19 Trial: a Pilot Study to Investigate Early Efficacy of MSCs in Adults With COVID-19 (clinicaltrials.gov) - P1/2; N=24; Recruiting; Sponsor: Cynata Therapeutics Limited

Clinical • New P1/2 trial • Acute Respiratory Distress Syndrome • Critical care • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CRP

A Study of CYP-001 for the Treatment of Steroid-Resistant Acute Graft Versus Host Disease (clinicaltrials.gov) - P1; N=16; Completed; Sponsor: Cynata Therapeutics Limited; Active, not recruiting ➔ Completed

Clinical • Trial completion • Graft versus Host Disease • Immunology